APP and Alzheimer disease: BCQA has been shown to attenuate scopolamine‐induced memory impairments in contextual fear conditioning tests, improve discriminating reversal learning in a transgenic mouse model of AD, control amyloidogenic APP processing in vitro, and reverse amphetamine‐induced hyperlocomotion, an in vivo antipsychotic efficacy testing (Conn et al., 2009; Ma et al., 2009).